Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
78641.300.5207%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

Ovid Therapeutics Inc

OVIDNASDAQ
Trade with Public
Trade with Public
$2.80
-0.13-4.44%
At close: Aug 28, 5:00 PM EST
$2.81
0.010.36%
After Hours: Aug 28, 6:53 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Ovid Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ovid Therapeutics (OVID).

Price Target Range — 10 Quarters

Analyst Consensus — 9 Analysts

8Buy
1Hold
Consensus RatingOutperform# Analysts9Avg. Consensus PT$4Upside to Avg. PT+57.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 3, 2026OppenheimerKostas BiliourisPT RaiseOutperform$7→$9
Apr 15, 2026WedbushLaura ChicoMaintainedOutperform$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Wedbush analyst Laura Chico reiterates Ovid Therapeutics (NASDAQ:OVID) with a Outperform and maintains $7 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $2 to $4.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Ovid Therapeutics, Raises Price Target to $7

Wedbush analyst Laura Chico maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $5 to $7.
Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $4

LifeSci Capital initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $2 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $2 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved